 |
Photo=Samsung Biologics |
[Alpha Biz= Reporter Kim Jisun] Samsung Biologics has announced a new contract for drug manufacturing valued at $1.24 billion (approx. 1.7 trillion KRW), marking the largest deal in the company's history. The contract, signed with an undisclosed Asian pharmaceutical company, is set to run until December 31, 2037.
This deal follows Samsung Biologics' recent $1.1 billion contract with a U.S.-based pharma firm in July, breaking the previous record just three months later. With this agreement, Samsung Biologics has secured a total of nine contracts this year, bringing its cumulative 2024 contract value to 4.36 trillion KRW, surpassing the 4 trillion KRW mark for the first time in its history.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
